We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Intelgenx (IGXT)
An SI Board Since July 2016
Posts SubjectMarks Bans
10 1 0
Emcee:  BioHero Type:  Moderated

Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there is another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .

IGXT has a ridiculous Market Cap of less than $32 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL

Intelgenx (IGXT)

Market Cap: $31.8 Million
Cash: $2.1 Million
Price: $0.49

Burn-Rate: $400k per Quarter
Shares Out : 63.6 Million


Big Partnership imminent :

•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016

Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017

Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017

Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014

IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.

 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
10Pullback creates a fantastic buying opp ..Partner deal news is around the cornerBioHero-8/25/2016
9 IGXT is in discussions with 33 Pharmaceutical Companies maybe sBioHero-8/23/2016
8Real Rally will start once we break the $1 Mark ... Enjoy the ride BioHero-8/18/2016
7A lot of new Partnerdeals on the way which means Upfront Payments to the CompanyBioHero-8/16/2016
6Nice Article Shorts tried hard to kill momentum yesterday but they will losBioHero-8/9/2016
5Great News released Friday after hour , now they have a lot of Cash for 3 years BioHero-8/8/2016
4gettint closer and closerr to the $1 mark and stock is still brutally undervalueBioHero-8/4/2016
3$1+ coming this is the right place for those who wants to make quick money becauBioHero-8/3/2016
2IGXT start moving get some before she explodes higher ,Big News like PartnershipBioHero-8/1/2016
1Here is one of the reason why i like this stock so much is because of this thinBioHero-7/27/2016
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):